{
    "clinical_study": {
        "@rank": "35194", 
        "arm_group": {
            "arm_group_label": "CAT-2003 or Placebo", 
            "arm_group_type": "Experimental", 
            "description": "All patients will receive placebo for a 14 day treatment period and CAT-2003 for a 28 day treatment period."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and efficacy of multiple doses of\n      CAT-2003 in patients with severe hypertriglyceridemia either naive or refractory to current\n      therapy. The study will evaluate effects of CAT-2003 on fasting and postprandial total\n      triglycerides and chylomicron triglyceride levels in patients with severe\n      hypertriglyceridemia.\n\n      This is a single-blind study. All patients will receive placebo for a 14 day treatment\n      period and CAT-2003 for a 28 day treatment period."
        }, 
        "brief_title": "Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hyperlipidemias", 
            "Hypertriglyceridemia", 
            "Dyslipidemias", 
            "Lipid Metabolism Disorders", 
            "Metabolic Diseases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hyperlipidemias", 
                "Hypertriglyceridemia", 
                "Metabolic Diseases", 
                "Lipid Metabolism Disorders", 
                "Sphingolipidoses", 
                "Dyslipidemias"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Between 18 and 74 years at Screening\n\n          -  Severe Hypertriglyceridemia (TG \u2265 500 mg/dL). If on lipid lowering therapy including\n             statins, fibrates,  and/or omega-3 fatty acids, stable dose for at least 4 weeks\n             prior to Screening\n\n          -  Body mass index (BMI) \u2264 45 kg/m2\n\n        Exclusion Criteria:\n\n          -  History of any major cardiovascular event within 6 months of Screening\n\n          -  Type I diabetes mellitus or use of insulin\n\n          -  History of pancreatitis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01968720", 
            "org_study_id": "CAT-2003-202"
        }, 
        "intervention": [
            {
                "arm_group_label": "CAT-2003 or Placebo", 
                "intervention_name": "CAT-2003", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CAT-2003 or Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33143"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46260"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auburn", 
                        "country": "United States", 
                        "state": "Maine", 
                        "zip": "04210"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45227"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Severe Hypertriglyceridemia", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percent change from baseline in fasting triglycerides in patients with severe hypertriglyceridemia", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01968720"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Safety will be assessed for all enrolled patients from the time the patient signs the informed consent through post-treatment follow-up.\nSafety parameters include physical exam, vital signs, clinical laboratory tests, ECGs and concomitant medications.", 
                "measure": "Frequency of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Absolute and percent change from baseline on postprandial total and chylomicron triglyceride levels", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Catabasis Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Catabasis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}